Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
MDGN > SEC Filings for MDGN > Form 8-K on 14-Mar-2013All Recent SEC Filings

Show all filings for MEDGENICS, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for MEDGENICS, INC.


Change in Directors or Principal Officers, Regulation FD Disclosure, Financial St

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 8, 2013, the Board of Directors of Medgenics, Inc., a Delaware corporation (the "Company"), elected Joseph J. Grano, Jr. to fill the vacancy in the Board of Directors created by the passing of Gary Brukardt. Such appointment will be effective as of March 15, 2013.

It has not yet been determined to which committees of the Board of Directors of the Company Mr. Grano will be appointed.

In connection with Mr. Grano's election as a Director and as inducement to his service, the Compensation Committee of the Company's Board of Directors approved the grant to Mr. Grano of stock options covering up to 300,000 shares of the Company's common stock, $0.0001 par value per share ("Common Stock"), at a per share exercise price of $4.99 (representing the closing price of the Common Stock on the NYSE MKT on March 7, 2013), subject to approval by the NYSE MKT of an additional listing application covering the issuance of the shares underlying such options. 100,000 shares underlying such options will vest upon grant and the remaining 200,000 shares will vest in equal installments on each of the first and second anniversaries of the effective date of Mr. Grano's appointment, subject to his continuous service through each vesting date. The options may only be exercised for cash and have a 5-year term. The grant is being made pursuant to a stand-alone award agreement outside of the Company's Stock Incentive Plan and qualifies as an inducement grant that does not require stockholder approval pursuant to Section 711 of the NYSE MKT Company Guide.

In addition, as of March 8, 2013, the Company and Mr. Grano entered into a Director Appointment Letter (the "Letter Agreement") setting forth, among other things, Mr. Grano's duties as a director. Pursuant to the Letter Agreement, Mr. Grano will be entitled to the same cash fees for his services as a director as the other non-executive directors pursuant to the director compensation plan previously adopted by the Board. These fees consist of a $15,000 annual retainer fee, as well as meeting fees that range between $1,000 and $2,000 per meeting based on location and type. The fees are fixed for a period of one year from the date of the Letter Agreement, following which they shall be subject to review. Pursuant to the Letter Agreement, Mr. Grano also agreed to maintain the confidentiality of all confidential business information, to disclose conflicts of interest to the Company and not to compete or solicit certain employees or other parties with which the Company does business for a period ending twelve months following the termination of his directorship.

The foregoing description of the Letter Agreement is qualified in its entirety by reference to the Letter Agreement, a copy of which is filed as Exhibit 10.1 to this Form 8-K and incorporated by reference herein.

Item 7.01 Regulation FD Disclosure.

Attached hereto as Exhibit 99.1 is a copy of the Company's press release, dated March 12, 2013, regarding the election of Mr. Grano.

The information furnished in this report under this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is furnished herewith:

Exhibit No.   Description

              Director Appointment Letter, dated as of March 8, 2013, between
10.1          Medgenics, Inc. and Joseph J. Grano, Jr.

              Medgenics, Inc. Press Release dated March 12, 2013 (furnished pursuant
99.1          to Item 7.01).

  Add MDGN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for MDGN - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.